Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 11-20 of 41 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2011Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MSRakhila, H.; Rozek, T.; Hopkins, A.; Proudman, S.; Cleland, L.; James, M.; Wiese, M.
2003Omega-6/Omega-3 fatty acids and arthritisCleland, L.; James, M.; Proudman, S.
2011Decline in hand bone mineral density indicates increased risk for erosive change in early rheumatoid arthritis (RA)Black, R.; Spargo, L.; Schultz, C.; Chatterton, B.; James, M.; Cleland, L.; Hill, C.; Proudman, S.; Australian Rheumatology Association in conjunction with Rheumatology Health Professionals Association 52nd Annual Scientific Meeting (14 May 2011 - 17 May 2011 : Brisbane, Qld.)
2012Decline in hand bone mineral density indicates increased risk for erosive change in early rheumatoid arthritis (RA)Black, R.; Spargo, L.; Shultz, C.; Chatteron, B.; James, M.; Cleland, L.; Lester, S.; Hill, C.; Proudman, S.; RACP Future Directions in Health Congress 2012 (06 May 2012 - 09 May 2012 : Brisbane, Qld.)
2007Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug useProudman, S.; Keen, H.; Stamp, L.; Lee, A.; Goldblatt, F.; Ayres, O.; Rischmueller, M.; James, M.; Hill, C.; Caughey, G.; Cleland, L.
2012Fish oil in rheumatoid arthritis: a randomised, double blind trial comparing high dose with low doseProudman, S.; Spargo, L.; Hall, C.; McWilliams, L.; Lee, A.; Rischmueller, M.; Gibson, R.; James, M.; Cleland, L.; Australian Rheumatology Association Annual Scientific Meeting (2012 : Canberra, A.C.T.)
2015Synovial fluid and plasma n3 long chain polyunsaturated fatty acids in patients with inflammatory arthritisMoghaddami, M.; James, M.; Proudman, S.; Cleland, L.
2016Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?Wabe, N.; Sorich, M.; Wechalekar, M.; Cleland, L.; McWilliams, L.; Lee, A.; Hall, C.; Spargo, L.; Metcalf, R.; Proudman, S.; Wiese, M.
2014Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritisWiese, M.; Alotaibi, N.; O'Doherty, C.; Sorich, M.; Suppiah, V.; Cleland, L.; Proudman, S.
2013Variability in genes that encode N-acetyl transferase 2 and ABCG2 and disease outcomes in early rheumatoid arthritisWiese, M.; Alotabi, N.; O'Doherty, C.; Sorich, M.; Suppiah, V.; Cleland, L.; Proudman, S.; Australian Rheumatology Association 54th Annual Scientific Meeting (18 May 2013 - 22 May 2013 : Perth, W.A.)